LiveNova Logo

TandemLife is now a part of LivaNova, Learn More Here.

COVID-19 UPDATES:The U.S. Food and Drug Administration (FDA) issued guidance on April 6, 2020 to temporarily expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19) public health emergency. As a result of the guidance, cardiopulmonary devices, including select devices from TandemLife | LivaNova, are now temporarily indicated for ECMO therapy greater than 6 hours. To read the full announcement, click here.

MENU

412 963 7770 GENERAL INFORMATION

855 336 3051 REIMBURSEMENT

800 373 1607 US

412 507 6182 INTERNATIONAL

Dr. Christopher Overgaard (Peter Munk Cardiac Centre – UHN) discusses his recent use of the TandemHeart Device

Posted on April 5, 2017 | Uncategorized

In his own words – TandemHeart – Dr. Christoper Overgaard

*Device duration varies by country.
Indications for Use – USA
  • TandemHeart Pump: The TandemHeart System is intended for extracorporeal circulatory support using an extracorporeal bypass circuit. Intended duration of use is for periods appropriate to cardiopulmonary bypass, up to six hours. It is also intended to be used as an extracorporeal circulatory support system (for periods up to six hours) for procedures not requiring complete cardiopulmonary bypass (e.g., valvuloplasty, mitral valve reoperation, surgery of the vena cava and/or aorta, liver transplant, etc.)
  • ProtekSolo 62 and 72 cm Transseptal Cannulae: The Transseptal Cannula Set-EF is intended for transseptal catheterization of the left atrium via the femoral vein for the purpose of providing a means for temporary (six hours or less) left ventricular bypass when connected to the TandemHeart extracorporeal blood pump, which returns blood to the patient via the femoral artery or other appropriate site.